New cancer drug GEN2 tested in patients – study halted early
Disease control
Terminated
This early-phase study tested a new drug called GEN2 in 37 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: GenVivo, Inc. • Aim: Disease control
Last updated May 18, 2026 12:08 UTC